Anticholinergic medications for reducing drooling in children with developmental disability

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology
• Developmental Disabilities

Background:

• Drooling (sialorrhea) is a common challenge in children with developmental disabilities, impacting quality of life.
• Anticholinergic medications are frequently used to manage excessive salivation.
• Limited comparative data exists on the effectiveness and side effect profiles of different anticholinergic agents in this population.

Purpose of the Study:

• To compare the effectiveness of benzhexol hydrochloride, glycopyrrolate, and scopolamine patches in reducing drooling.
• To assess the frequency and nature of adverse events associated with these medications.
• To determine the impact of side effects on treatment discontinuation rates.

Main Methods:

• A 5-year prospective study involving 110 children with developmental disabilities receiving anticholinergic treatment.
• Data collection on drooling severity, medication compliance, adverse effects, and reasons for cessation over 52 weeks.
• Statistical analysis using survival analysis and proportional hazards regression to compare outcomes and identify predictors of discontinuation.

Main Results:

• Benzhexol, glycopyrrolate, and scopolamine showed response rates of 85%, 75%, and 65%, respectively.
• Glycopyrrolate was associated with the fewest side effects.
• Adverse events frequently led to treatment cessation, particularly in males, with behavioral issues prompting benzhexol cessation more often in males.

Conclusions:

• All three anticholinergic medications can reduce drooling in children with developmental disabilities.
• Glycopyrrolate offers the most favorable balance of efficacy and tolerability.
• Poor head control and oromotor function predict poorer treatment response, and side effects are a significant factor in treatment discontinuation.